hit counter
Allena Pharmaceuticals, Inc. (ALNA) Stock News Sentiment & Price - Sentifly
ALNA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Allena Pharmaceuticals, Inc. (ALNA)

USA
Biotechnology
NASDAQ
ALNA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALNA Latest news
GlobeNewsWire
Neutral
Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress
2021-11-10 16:05

NEWTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the third quarter and nine months ended September 30, 2021, and highlighted recent corporate progress.

PennyStocks
Positive
Hot Penny Stocks to Watch as AMC and GME Go to the Moon
2021-11-03 13:15

Which penny stocks are you watching as GME stock and AMC stock shoot toward the moon? The post Hot Penny Stocks to Watch as AMC and GME Go to the Moon appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Pulse2
Positive
ALNA Stock: Why The Price Surged Today
2021-11-03 11:10

The stock price of Allena Pharmaceuticals Inc (NASDAQ: ALNA) increased by over 20% during intraday trading today. This is why it happened.

GlobeNewsWire
Neutral
Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress
2021-08-10 16:30

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate progress.

GlobeNewsWire
Neutral
Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference
2021-08-03 16:15

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12th Annual Wedbush PacGrow Healthcare Conference on August 10th – August 11th, 2021.

GlobeNewsWire
Neutral
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2021-08-03 16:05

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee's entry into employment with the Company.

Pulse2
Negative
ALNA Stock Fell 35.04%: Why It Happened
2021-07-15 01:14

The stock price of Allena Pharmaceuticals Inc (NASDAQ: ALNA) fell by 35.04%. This is why it happened.

Benzinga
Negative
Allena Pharma Stock Under Pressure After Equity Raise Of $28M
2021-07-14 07:08

Allena Pharmaceuticals Inc (NASDAQ: ALNA) has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311. With gross proceeds of $28 million, the offering will close by July 16.

GlobeNewsWire
Neutral
Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
2021-07-13 23:43

NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 10,678,872 shares of the Company's common stock, at a purchase price of $1.311 per share of common stock (or common stock equivalent) and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions.

Loading more news...